PuriCore plc ("PuriCore or the "Company")

Grant of Options

(AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, announces the grant of share options to Alex Martin, CEO-designate, to subscribe for up to 1,000,000 new ordinary shares of 10p each in the capital of the Company (the "Options").

The Options, granted on 5 June 2015, have an exercise price of 29.75 pence each and a five year term. The Option s vest one-third per year on each of the three anniversaries of the grant date, subject to the achievement of performance conditions relating to the financial and strategic targets. Alex Martin holds no other options over shares in the Company.

-Ends-

Enquiries:

PuriCore plc

+44 (0) 20 3727 1000

Charles Spicer, Non-Executive Chairman

Marella Thorell, Chief Financial Officer and Chief Operating Officer








FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan / Victoria Foster Mitchell






N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell / Jen Boorer / Thomas Smale




About PuriCore

PuriCore is an international company focused on developing and commercialising safe and effective products to protect against the spread of infectious pathogens based on its proprietary hypochlorous acid platform technology. Its products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment.

In the Supermarket Retail segment, PuriCore offers products to US retailers for use in their fresh produce departments to improve food safety and quality, to extend shelf life and to decrease food wastage. Our product is an eco-friendly, food-safe sanitising solution at a neutral PH that is used to protect produce from cross contamination and improve freshness. Our Sterilox Fresh Systems are capital equipment that are installed at customer locations and allow for generation of solution as needed at the store. ProduceFresh is our concentrate bottled version providing the same levels of stability, freshness and quality in a convenient consumable package. Additionally, the Company's FloraFresh ®products, also sold as a concentrate in bottled form, protect against fungal growth and extend the life of cut flowers, with an initial focus on supermarket floral departments.

In Health Sciences, PuriCore's Wound Care business provides products that are used to treat chronic and acute wounds, including diabetic ulcers and burns in humans. A range of products have also been developed to manage wounds in companion and farm animals. The Company's Dermatology business is currently focused on treatments for atopic dermatitis. PuriCore is headquartered in Malvern, Pennsylvania.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.


This information is provided by RNS
The company news service from the London Stock Exchange
ENDMSCUGUGUQUPAGQB
distributed by